Provided by Tiger Trade Technology Pte. Ltd.

ProShares Ultra Nasdaq Biotechnology

112.06
+2.252.05%
Post-market: 112.240.1850+0.17%16:15 EDT
Volume:10K
Turnover:1.07M
Market Cap:94.13M
PE:- -
High:112.69
Open:110.00
Low:108.00
Close:109.80
52wk High:126.40
52wk Low:62.72
Shares:840.00K
Float Shares:840.00K
Volume Ratio:1.46
T/O Rate:1.15%
Dividend:0.22
Dividend Rate:0.20%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

LIVE Markets-Europe Before the Bell: Eyeing Another Soft Open

Reuters
·
Sep 09

Amgen Shares Plunge to Decade Low After Rival Drug Trial Fails, BMO Cuts Rating

Stock News
·
Sep 09

Analysts Conflicted on These Healthcare Names: Amgen (AMGN), Beam Therapeutics (BEAM) and Royalty Pharma (RPRX)

TIPRANKS
·
Sep 09

Money Quote: a Bad Day for Amgen Stock

Dow Jones
·
Sep 09

Assembly Biosciences Exercises U.S. Profit-Share Option for Herpes Program with Gilead

Dow Jones
·
Sep 09

Gilead Sciences Inc. Stock Underperforms Tuesday When Compared to Competitors

Dow Jones
·
Sep 09

AMD, Amgen, Novartis, Qualcomn, Corning, and More Stocks That Explain Today's Market

Dow Jones
·
Sep 09

LIVE Markets-Back to the Post-Summer Grind: Stocks End Red

Reuters
·
Sep 09

US Equity Markets End Lower After Houthi Attack on Saudi Arabia Energy Facilities

MT Newswires Live
·
Sep 09

Assembly Bio Highlights Phase 2 Starts for ABI-6250, GS-1179 in Pipeline Update

Reuters
·
Sep 09

Structure weakness ‘disconnected’ from underlying data, says Jefferies

TIPRANKS
·
Sep 09

Assembly Biosciences Exercises U.S. Profit-Share Option with Gilead for Hsv Helicase-Primase Inhibitor Program

THOMSON REUTERS
·
Sep 09

Assembly Biosciences - Assembly Bio Eligible for up to $280 Mln in Milestones and Royalties Outside U.S.

THOMSON REUTERS
·
Sep 09

Assembly Biosciences - Gs-1179 Expected to Advance into Phase 2 Trial for Genital Herpes by End of 2026

THOMSON REUTERS
·
Sep 09

Assembly Biosciences - Gilead Retains Sole Right for Clinical Development and Commercialization of Hsv Hpi Program

THOMSON REUTERS
·
Sep 09

Amgen Stock Poised for Worst Day in More than Two Decades

Dow Jones
·
Sep 09

Vertex Pharmaceuticals Inc Stock (VRTX) Moved Down by 3.06% on Sep 8: What Signal Does It Send?

TradingKey
·
Sep 09

Top Midday Decliners

MT Newswires Live
·
Sep 09

Gilead Sciences Inc Stock (GILD) Moved Down by 3.26% on Sep 8: Drivers Behind the Movement

TradingKey
·
Sep 09

Amgen's Olpasiran May Still Show Heart-Risk Reduction Despite Novartis Miss, UBS Says

MT Newswires Live
·
Sep 09